We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BlackRock Asset Management Ireland Limited iShares Nasdaq US Biotechnology UCITS ETF (BTEK)

Sell:£5.20 Buy:£5.21 0 Change: £0.02 (0.39%)
Market closed Prices as at close on 3 October 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:£5.20
Buy:£5.21
Change: £0.02 (0.39%)
Market closed Prices as at close on 3 October 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:£5.20
Buy:£5.21
Change: £0.02 (0.39%)
Market closed Prices as at close on 3 October 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
£5.18
Trade high:
£5.24
Year high:
£5.56
Market Listing:
London
Previous close:
£5.18
Trade low:
£5.20
Year low:
£4.30
Size:
$519.98M
Previous:
£0.04 (0.68%)
Previous:
£0.04
Volume:
14,464
Dividend yield:
n/a
Currency:
GBP
Data delayed by at least 15 minutes.

ETP Basics

Issuer: n/a
Structure: n/a
Replication method: n/a
Securities lending: No
Number of holdings: 271
Size: $520M
Launch date: 19 October 2017
Launch price: n/a
UCITS: n/a
Reporting status: n/a
Domicile: Ireland
Complex product: Non-complex
ISIN: IE00BYXG2H39

Annual & interim reports

Ready to invest?

Invest now

Want to invest?

To buy shares in , you'll need to have an account.

Explore the options

Important Documents

There are no documents available for this stock.

OBJECTIVE

Index: Nasdaq Biotechnology Index(R)
Aim: The Share Class is a share class of a Fund which aims to achieve a return on your...
Read full aim for BlackRock Asset Management Ireland Limited
Leverage: n/a
Currency hedging: n/a

COSTS

Ongoing Charge (OCF/TER): 0.35%
Management fee: n/a
Indicative spread: 0.19%

In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.

Performance

1 week 1W 0.88% 1 year 1Y 11.01%
1 month 1M 3.74% 2 years 2Y 4.4%
3 months 3M 0.44% 3 years 3Y 1.14%
6 months 6M 3.88% 5 years 5Y 45.76%

Performance figures are based on the previous close price. Past performance is not an indication of future performance.

Security Weight
VERTEX PHARMACEUTICALS INC 8.12%
AMGEN 8.06%
REGENERON PHARMACEUTICALS INC 7.99%
GILEAD SCIENCES INC 7.95%
MODERNA INC 4.76%
ASTRAZENECA 4.09%
BIOGEN 4.07%
SEAGEN INC 3.46%
ILLUMINA 3.01%
HORIZON THERAPEUTICS 2.35%
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Data provided by Broadridge. Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties. Securities lending data correct as at date not available. Charge data correct as at date not available. Holdings correct as at 30 April 2023.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.